No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Indoco Remedies Limited, headquartered in Mumbai, India, is a diversified pharmaceutical company founded in 1945 (formerly Indo Continental Trading Company). The company specializes in the development, manufacturing, marketing, and global distribution of both active pharmaceutical ingredients (APIs) and a broad spectrum of finished drug formulations. Their extensive product portfolio addresses numerous medical fields, including oral care, digestive health, respiratory ailments, anti-infectives, nutritional supplements, ophthalmology, antifungal treatments, hormonal therapies, dermatology, urology, diabetes management, gynaecological solutions, lifestyle products, pain management, and cardiovascular medicines. Additionally, Indoco offers a diverse range of branded generic pharmaceuticals, such as analgesic tablets and topical preparations, antihypertensive medications, protein supplements, multivitamin tablets and syrups, various antibiotic forms (tablets, syrups, and injectables), oral rehydration powders, anti-haemorrhoidals, antacids, and antihistamines. Beyond its core pharmaceutical production, Indoco Remedies provides comprehensive analytical testing services. These include impurity profiling, particle size analysis, polymorphism and compatibility studies, heavy metal detection, extractables and leachables assessments, lyophilization investigations, reference and working standards development, forced degradation studies, and chromatographic method development and validation. The company also extends its expertise to a suite of engineering and project management services, encompassing architectural design, lighting, mechanical and utility engineering, project and construction management, electrical systems, control system integration, piping, structural design, data transfer systems, and process engineering solutions. Furthermore, Indoco is a key provider of contract research and manufacturing services (CRAMS). This includes custom synthesis of molecules and intermediates, advanced process chemistry research and development, designing and scaling up non-infringing processes, and developing and validating analytical methods, alongside comprehensive contract manufacturing capabilities.
www.indoco.comNo one on the platform currently holds INDOCO.BO.
No tracked institution reports a position in INDOCO.BO as of their last filing.
No one on the platform has traded INDOCO.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 10.8% | 8.7% | ||||
| Profit Margin % | -5.3% | 2.9% | 3.5% | |||
| Free Cash Flow Margin % | -6.2% | -7.9% | -4.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $20.5B | +16.3% | $4.65 | $2.04–$6.58 | — | 2 |
| 2028 | $23.2B | +13.2% | $11.82 | $9.05–$13.33 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | $-3.60 | $7.10 | +297.2% |
| 2026-05-07 | $-3.55 | $-2.30 | +35.2% |
| 2026-02-03 | $-2.55 | $-3.20 | -25.5% |
| 2025-10-22 | $-3.00 | $-0.80 | +73.3% |
| 2025-07-24 | $-3.95 | $-3.95 | -0.1% |
| 2025-05-22 | $1.65 | $-4.40 | -366.7% |
| 2025-01-21 | $-1.50 | $-3.05 | -103.3% |
| 2024-10-24 | $1.75 | $-1.05 | -160.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| INDOCO.BOIndoco Remedies Limited | $242.05 | -7.91% | $22.2B | — |
| ALEMBICLTD.NSAlembic Limited | $100.51 | -3.66% | $25.8B | — |
| HIKAL.BOHikal Limited | $212.35 | -6.47% | $26.1B | — |
| HIKAL.NSHikal Limited | $212.22 | -5.66% | $26.2B | — |
| IOLCP.BOIOL Chemicals and Pharmaceuticals Limited |
| $179.45 |
| -7.26% |
| $52.7B |
| — |
| IOLCP.NSIOL Chemicals and Pharmaceuticals Limited | $179.52 | -7.61% | $52.7B | — |
| MOREPENLAB.BOMorepen Laboratories Limited | $106.25 | -8.37% | $58.3B | — |
Source: Financial Modeling Prep · peers by sector/industry